Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells 4,683 Shares of Stock

April 3, 2026 by InsiderTrades.com

Key Points

Ultragenyx CFO Howard Horn sold 4,683 shares on April 1 at an average price of $20.97 (total ~$98,202), executed under a pre‑arranged Rule 10b5‑1 plan and reducing his stake by about 5.51% to 80,351 shares (≈$1.685M).
The company faces mixed catalysts: a cited positive DTX301 Phase‑3 readout but a recent quarterly EPS miss (‑$1.29 vs. ‑$1.20 consensus) even as revenue rose 25.5%, and a looming class‑action overhang with multiple plaintiff firms soliciting lead‑plaintiff inquiries ahead of an April 6 deadline.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CFO Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $20.97, for a total transaction of $98,202.51. Following the completion of the sale, the chief financial officer directly owned 80,351 shares in the company, valued at approximately $1,684,960.47. This represents a 5.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Howard Horn also recently made the following trade(s):

On Tuesday, March 3rd, Howard Horn sold 1,635 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $22.40, for a total value of $36,624.00.
On Monday, March 2nd, Howard Horn sold 8,409 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $22.70, for a total value of $190,884.30.
On Monday, February 2nd, Howard Horn sold 3,061 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $23.56, for a total transaction of $72,117.16.

Ultragenyx Pharmaceutical Trading Up 4.8%

RARE opened at $22.45 on Friday. The company has a market cap of $2.21 billion, a PE ratio of -3.84 and a beta of 0.25. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.29 and a 12 month high of $42.37. The company has a 50 day moving average of $22.23 and a 200 day moving average of $27.81.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.09). The company had revenue of $207.28 million for the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The business's revenue for the quarter was up 25.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.39) earnings per share. Research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. increased its position in shares of Ultragenyx Pharmaceutical by 614.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company's stock valued at $65,205,000 after acquiring an additional 1,864,164 shares in the last quarter. Norges Bank purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter valued at $29,004,000. Millennium Management LLC boosted its stake in Ultragenyx Pharmaceutical by 787.6% during the 4th quarter. Millennium Management LLC now owns 880,644 shares of the biopharmaceutical company's stock valued at $20,255,000 after purchasing an additional 781,431 shares during the last quarter. Vestal Point Capital LP bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth $22,560,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Ultragenyx Pharmaceutical by 599.2% in the third quarter. Russell Investments Group Ltd. now owns 840,451 shares of the biopharmaceutical company's stock worth $25,281,000 after purchasing an additional 720,256 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

Positive Sentiment: Positive Phase‑3 readout cited as a catalyst — Coverage highlights favorable results from the DTX301 Phase‑3 Enh3ance study (AAV8 gene therapy for OTC deficiency), a clinical win that supports Ultragenyx’s pipeline value and could underpin upside expectations if regulators/partners view data favorably. Ultragenyx (RARE) Shares Positive Results From DTX301 Phase 3 Study
Neutral Sentiment: CFO Howard Horn sold 4,683 shares under a pre‑arranged Rule 10b5‑1 plan; holding still substantial — Insider sale disclosed at an average price of $20.97, reducing his stake by ~5.5%; because it was a scheduled 10b5‑1 trade, the market generally treats this as routine rather than a signal of undisclosed negative information. Howard Horn Insider Sale
Negative Sentiment: Heavy legal notices and looming lead‑plaintiff deadline create overhang — Multiple plaintiff firms (Rosen, ClaimsFiler, Schall, Pomerantz, Bronstein Gewirtz, Levi & Korsinsky, Berger Montague, KSF) are soliciting lead‑plaintiff inquiries for a securities class action covering Aug 3, 2023–Dec 26, 2025, with an April 6 deadline. That surge in filings/solicitations signals a substantive class‑action matter that could lead to discovery, legal costs or settlements, and tends to pressure shares until resolution or clearer implications are known. Representative notices: Rosen (GlobeNewswire), ClaimsFiler (GlobeNewswire), Schall Law (GlobeNewswire), Pomerantz (PR Newswire). Rosen Law Firm Notice ClaimsFiler Notice Schall Law Notice Pomerantz Notice

Analyst Ratings Changes

Several research firms recently weighed in on RARE. Robert W. Baird decreased their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an "outperform" rating on the stock in a research report on Tuesday, December 30th. Wedbush reaffirmed a "neutral" rating and set a $25.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Weiss Ratings restated a "sell (e+)" rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 21st. Wells Fargo & Company cut their target price on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an "overweight" rating on the stock in a research note on Tuesday, December 30th. Finally, Canaccord Genuity Group reduced their price objective on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a "buy" rating on the stock in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and a consensus target price of $60.47.

Get Our Latest Research Report on RARE

Ultragenyx Pharmaceutical Company Profile

(Get Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.